{"id":23163,"date":"2023-05-30T20:44:06","date_gmt":"2023-05-30T15:14:06","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=23163"},"modified":"2023-08-17T14:55:00","modified_gmt":"2023-08-17T09:25:00","slug":"ad109-for-obstructive-sleep-apnea","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea","title":{"rendered":"ATS 2023 Updates: AD109&#8217;s Potential as the First Oral Medication for Obstructive Sleep Apnea (OSA)"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em>Apnimed\u2019s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue.<\/em><\/li>\n\n\n\n<li><em>The dual mode of action of AD109 leads to&nbsp;upper airway dilatation as well as enhanced breathing and oxygenation during sleep.<\/em><\/li>\n\n\n\n<li><em>Results of the MARIPOSA Phase IIb trial, an efficacy, safety, and dose-finding study for AD109 support the advancement of the drug to Phase III.<\/em><\/li>\n\n\n\n<li><em>If successful, AD109 could substantially alter the treatment of patients with varying disease intensities ranging from symptomatic snoring to more severe OSA.<\/em><\/li>\n<\/ul>\n\n\n\n<p>Sleep disorders have become a major public health concern that affects millions of North Americans. Obstructive sleep apnea (OSA) is the most common type of sleep-related breathing disorder, marked by abnormal breathing during sleep. This life-altering disorder is characterized by episodes of a complete (apnea) or partial collapse (hypopnea) of the upper airway with an associated decrease in oxygen saturation or arousal from sleep. It occurs when the muscles in the back of the throat fail to keep the airway open, causing brief episodes of breathing cessation. As per Delveinsight\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-epidemiology-forecast\" class=\"ek-link\">Obstructive Sleep Apnea Epidemiology report<\/a>, in 2022, there were approximately <strong>7.6 million<\/strong> males and <strong>5.7 million<\/strong> females with OSA in the US.&nbsp;<\/p>\n\n\n\n<p>OSA is a serious condition that can have significant health consequences if left untreated. The treatment of OSA aims to alleviate the symptoms, improve sleep quality, and reduce associated health risks. The specific treatment options may vary depending on the severity of the condition. Weight loss and exercise, CPAP therapy (the <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market\" class=\"ek-link\">first line of treatment for OSA<\/a>), bilevel-positive airway pressure (BPAP) equipment (if CPAP therapy is ineffective), and surgery are the recommended treatments for the illness. Excessive Daytime Sleepiness, the most common OSA-associated condition is treated with drugs such as <strong>modafinil<\/strong>,<strong> armodafinil<\/strong>, <strong>solriamfetol<\/strong>,<strong> pitolisant<\/strong>,<strong> <\/strong>and<strong> <\/strong>others. However, no drugs currently exist to treat OSA directly.&nbsp;<\/p>\n\n\n\n<p><strong>Apnimed <\/strong>is one of the few companies actively engaged in developing potential treatments for OSA and other sleep-related disorders. Its oral pharmaceutical drug addresses the disease&#8217;s underlying neurobiology to stimulate upper airway muscles and keep an open airway during sleep. <strong>Apnimed\u2019s<\/strong> <strong>AD109 (aroxybutynin + atomoxetine)<\/strong> is a first-in-class, oral pharmaceutical combination dosed <strong>once daily<\/strong> at bedtime; the US FDA has granted it <strong>Fast Track Designation<\/strong>. Through a dual mode of action, the medication targets two neurochemical pathways that govern the upper airway musculature during sleep. It combines a <strong>selective norepinephrine reuptake inhibitor, atomoxetine<\/strong>, with a <strong>novel selective antimuscarinic, aroxybutynin<\/strong>.&nbsp;<\/p>\n\n\n\n<p>At the recently held <strong>American Thoracic Society (ATS) International Conference, 2023<\/strong>, for the first time, the company presented positive <strong>MARIPOSA<\/strong> <strong>Phase IIb (NCT05071612)<\/strong> results on AD109, an investigational <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market\" class=\"ek-link\">oral drug for OSA<\/a>. A total of 294 participants with OSA severity ranging from mild to severe (<strong>Apnea-Hypopnea Index (AHI4, 4% desaturation criteria for hypopneas)<\/strong> of 10\u231045) participated in this Phase IIb trial at 25 sites across the United States. Enrollment was available to both treatment-naive individuals and a significant proportion of <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-epidemiology-forecast\" class=\"ek-link\">OSA patients<\/a> who refused or were unable to tolerate treatment with positive airway pressure devices (e.g., CPAP), the current standard of care therapy for OSA.<\/p>\n\n\n\n<p>The MARIPOSA trial showed that both dosages of AD109 tested demonstrated a statistically significant reduction in AHI4 as compared to the placebo. In the <strong>AD109 2.5mg\/75mg dose<\/strong>, <strong>AHI4 <\/strong>was reduced from a median of <strong>20.5 to 10.8 events\/hour.<\/strong> Overall, <strong>41% <\/strong>of people who finished the trial had an <strong>AHI of less than 10<\/strong>, <strong>44%<\/strong> <strong>had a higher than 50% drop<\/strong> from baseline, and <strong>15% had an 80% or more reduction<\/strong>. The administration of AD109 resulted in clinically significant decreases in AHI in the majority of individuals with mild, moderate, and severe OSA.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/obstructive-sleep-apnea-osa-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic-1024x194.png\" alt=\"Obstructive Sleep Apnea Market Infographic\" class=\"wp-image-23216\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/31100939\/Obstructive-Sleep-Apnea-Market-Infographic.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>The MARIPOSA findings confirm AD109&#8217;s ability to <strong>alleviate OSA-related daytime symptoms<\/strong>. A statistically significant improvement in patients taking AD109 (aroxybutynin 2.5mg\/atomoxetine 75mg) versus placebo was reported on a daytime functioning assessment called <strong>PROMIS-Fatigue (recommended to Apnimed by the FDA)<\/strong>. Further, AD109 demonstrated statistically significant improvements on other OSA symptom-evaluating scales like <strong>PROMIS-Sleep Impairment<\/strong> and <strong>PROMIS-Sleep Disturbance<\/strong>.&nbsp;<\/p>\n\n\n\n<p>The trial findings also indicated that atomoxetine alone is an ineffective treatment for OSA. Atomoxetine (as monotherapy) did not improve daytime OSA symptoms and significantly impacted nocturnal sleep, both subjectively and by Total Sleep Time (TST). AD109 was well accepted and safe. During the trial, there were no major adverse events (SAEs) and no new or unexpected adverse events. The most prevalent side effects in AD109 patients were dry mouth, sleeplessness, and nausea.&nbsp;<\/p>\n\n\n\n<p>Following successful discussions with the US FDA in February 2023, Apnimed intends to progress AD109 into <strong>Phase III<\/strong>. The company plans to submit additional findings and analyses at upcoming scientific conferences. According to key opinion leaders, as the investigational addresses some of the major shortcomings of the current standard-of-care treatments that are poorly tolerated (e.g., CPAP and oral devices) and\/or intrusive (e.g., surgery or implanted devices), there is hope that AD109 may become one of the more important treatments for OSA.&nbsp;Among the <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-pipeline-insight\">emerging drugs in the OSA pipeline<\/a>, there are limited drugs that could make it to launch to fill the gaps in the treatment, most of them small molecules. The OSA market remains highly opportunistic and untouched. With not many new agents being developed and tested as potential treatments for OSA, AD109 is expected to reign the OSA market until any new therapy receives approval.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast-1024x256.png\" alt=\"\" class=\"wp-image-23165\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30170654\/Obstructive-Sleep-Apnea-Market-Outlook-and-Forecast.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Sleep disorders have become a major public health concern that affects millions of North Americans. Obstructive sleep apnea (OSA) is the most common type of sleep-related breathing disorder, marked by abnormal breathing during sleep. This life-altering disorder is characterized by episodes of a complete (apnea) or partial collapse (hypopnea) of the upper airway with an [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":23178,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":4,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20735,20731,16800,2858,2319,2843],"industry":[17225],"therapeutic_areas":[17506],"class_list":["post-23163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-american-thoracic-society-2023","tag-apnimed","tag-atsena-therapeutics","tag-obstructive-sleep-apnea","tag-osaka-university","tag-sleep-disorder","industry-pharmaceutical","therapeutic_areas-sleep-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evaluating Apnimed\u2019s AD109 for Obstructive Sleep Apnea (OSA)<\/title>\n<meta name=\"description\" content=\"Apnimed\u2019s AD109 has the potential to be the first oral drug that can address the primary cause of Obstructive Sleep Apnea, nocturnal airway\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluating Apnimed\u2019s AD109 for Obstructive Sleep Apnea (OSA)\" \/>\n<meta property=\"og:description\" content=\"Apnimed\u2019s AD109 has the potential to be the first oral drug that can address the primary cause of Obstructive Sleep Apnea, nocturnal airway\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-30T15:14:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-17T09:25:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30171138\/Obstructive-Sleep-Apnea-Market-Outlook.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evaluating Apnimed\u2019s AD109 for Obstructive Sleep Apnea (OSA)","description":"Apnimed\u2019s AD109 has the potential to be the first oral drug that can address the primary cause of Obstructive Sleep Apnea, nocturnal airway","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea","og_locale":"en_US","og_type":"article","og_title":"Evaluating Apnimed\u2019s AD109 for Obstructive Sleep Apnea (OSA)","og_description":"Apnimed\u2019s AD109 has the potential to be the first oral drug that can address the primary cause of Obstructive Sleep Apnea, nocturnal airway","og_url":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-05-30T15:14:06+00:00","article_modified_time":"2023-08-17T09:25:00+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30171138\/Obstructive-Sleep-Apnea-Market-Outlook.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea","url":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea","name":"Evaluating Apnimed\u2019s AD109 for Obstructive Sleep Apnea (OSA)","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30171138\/Obstructive-Sleep-Apnea-Market-Outlook.png","datePublished":"2023-05-30T15:14:06+00:00","dateModified":"2023-08-17T09:25:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Apnimed\u2019s AD109 has the potential to be the first oral drug that can address the primary cause of Obstructive Sleep Apnea, nocturnal airway","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/ad109-for-obstructive-sleep-apnea#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30171138\/Obstructive-Sleep-Apnea-Market-Outlook.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30171138\/Obstructive-Sleep-Apnea-Market-Outlook.png","width":1200,"height":800,"caption":"Obstructive Sleep Apnea Market Outlook"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/30171138\/Obstructive-Sleep-Apnea-Market-Outlook-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">American Thoracic Society 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Apnimed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atsena Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obstructive sleep apnea<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osaka University<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">sleep disorder<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">American Thoracic Society 2023<\/span>","<span class=\"advgb-post-tax-term\">Apnimed<\/span>","<span class=\"advgb-post-tax-term\">Atsena Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">obstructive sleep apnea<\/span>","<span class=\"advgb-post-tax-term\">Osaka University<\/span>","<span class=\"advgb-post-tax-term\">sleep disorder<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 30, 2023","modified":"Updated on Aug 17, 2023"},"absolute_dates_time":{"created":"Posted on May 30, 2023 8:44 pm","modified":"Updated on Aug 17, 2023 2:55 pm"},"featured_img_caption":"Obstructive Sleep Apnea Market Outlook","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=23163"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23163\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/23178"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=23163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=23163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=23163"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=23163"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=23163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}